Technical Analysis for CORI - Corium International, Inc.

Grade Last Price % Change Price Change
grade C 8.93 -2.93% -0.27
CORI closed down 2.93 percent on Tuesday, September 18, 2018, on approximately normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical CORI trend table...

Date Alert Name Type % Chg
Sep 18 New Downtrend Bearish 0.00%
Sep 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Sep 18 Bollinger Band Squeeze Range Contraction 0.00%
Sep 18 Stochastic Reached Oversold Weakness 0.00%
Sep 18 BB Squeeze + Lower Band Touch Range Contraction 0.00%
Sep 18 Below Lower BB Weakness 0.00%
Sep 18 Lower Bollinger Band Touch Weakness 0.00%
Sep 18 Oversold Stochastic Weakness 0.00%
Sep 17 Fell Below 20 DMA Bearish -2.93%
Sep 17 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -2.93%

Older signals for CORI ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Corium International, Inc., a biopharmaceutical company, focuses on the research, development, manufacture, and commercialization of specialty pharmaceutical products. Its products include Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for management of chronic pain, including cancer-related pain; Crest Whitestrips, a series of four products under the Advanced Vivid, Professional Effects, One Hour Express, and Flex-Fit brands for oral care. The company is also developing AG200-15, a combination hormonal contraceptive patch in Phase III clinical trials that delivers ethinyl estradiol and levonorgestrel hormones; MicroCor hPTH(1-34), a transdermal system, which has completed Phase I clinical trials for the treatment of severe osteoporosis; and Corplex Tamsulosin that has completed Phase I clinical trials for the treatment of benign prostatic hyperplasia. In addition, its products that have completed development, scale-up, and clinical activities include motion sickness patch for the prevention of nausea and vomiting associated with motion sickness; and urology patch for treatment of a urologic condition. Further, the company is developing Donepezil and Memantine transdermal patches for the treatment of Alzheimer's disease; and Ropinerole and Pramipexole therapies for the treatment of Parkinson's disease. Corium International, Inc. has collaboration agreements with The Procter & Gamble Company, Teva Pharmaceuticals USA, Inc., Par Pharmaceutical, Inc., and Agile Therapeutics, Inc. The company was incorporated in 1995 and is headquartered in Menlo Park, California.
Is CORI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 13.93
52 Week Low 7.17
Average Volume 203,718
200-Day Moving Average 10.1345
50-Day Moving Average 8.5649
20-Day Moving Average 9.4563
10-Day Moving Average 9.4155
Average True Range 0.3477
ADX 25.99
+DI 17.6809
-DI 21.3001
Chandelier Exit (Long, 3 ATRs ) 8.8669
Chandelier Exit (Short, 3 ATRs ) 9.6331
Upper Bollinger Band 9.9782
Lower Bollinger Band 8.9344
Percent B (%b) 0.0
BandWidth 11.038144
MACD Line 0.1653
MACD Signal Line 0.2804
MACD Histogram -0.1151
Fundamentals Value
Market Cap 319.17 Million
Num Shares 35.7 Million
EPS -1.72
Price-to-Earnings (P/E) Ratio -5.19
Price-to-Sales 10.96
Price-to-Book 12.08
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.35
Resistance 3 (R3) 9.40 9.30 9.28
Resistance 2 (R2) 9.30 9.20 9.28 9.26
Resistance 1 (R1) 9.12 9.13 9.07 9.07 9.23
Pivot Point 9.02 9.02 9.00 9.00 9.02
Support 1 (S1) 8.84 8.92 8.79 8.79 8.63
Support 2 (S2) 8.74 8.85 8.72 8.60
Support 3 (S3) 8.56 8.74 8.58
Support 4 (S4) 8.51